Profusa Advances Lumee Oxygen Platform Toward CE Mark
Profusa (PFSA) received a positive ISO 13485 decision from GMED, advancing its Lumee Oxygen Platform toward CE marking in the EU. The platform monitors tissue oxygen levels. Profusa expects ISO certification in early October but cautions on timing uncertainties. PFSA stock is up 86.82% in pre-market trading.
How this was made
The 30-second read
Why it matters
ISO 13485 certification is a prerequisite for CE marking, a key step for EU commercialization.
Market read
First‑report of regulatory progress; could influence PFSA price if EU launch proceeds.
What to watch
Potential regulatory delays and competition from larger med‑tech players.
Background
Profusa is a digital health company developing injectable biosensors for continuous tissue oxygen monitoring.
Ticker impact
Profusa received a positive ISO 13485 decision, a step toward CE marking of its Lumee Oxygen Platform.
potential upside if CE mark is obtained, but near‑term volatility expected.
Regulatory approval is material for a micro‑cap medical‑device firm, yet timing and final outcome remain uncertain.
Market effects
May boost confidence in EU‑focused med‑tech firms.
Limited to European medical‑device market outlook.
Low; primarily affects Profusa and niche investors.
Counterpoint
The CE‑mark process could stall, making the news overhyped.
Key entities
- companyProfusa, Inc.
Developer of the Lumee Oxygen Platform.
- organizationGMED
EU notified body conducting the certification.